Erupção Acneiforme Refratária Reveladora de Doença de Behçet: A Propósito de um Caso Clínico com Resposta Tardia mas Eficaz ao Adalimumab
Resumo
A doença de Behçet é uma vasculite sistémica crónica e recidivante que pode levar a um aumento significativo da morbilidade e mortalidade. Após superar o desafio em fazer o seu diagnóstico atempado, que muitas vezes se impõe, surge a dificuldade no seu tratamento. Relata-se um caso de um doente que se apresentou com uma erupção acneiforme reveladora de doença de Behçet, refratária à terapia convencional, que respondeu mais tarde e completamente, ao adalimumab. Na literatura científica, embora faltem ensaios clínicos controlados e randomizados, há já evidência significativa que suporta o papel dos agentes anti-TNF como um importante avanço terapêutico na doença de Behçet, particularmente em casos graves, refratários ou intolerantes à imunossupressão clássica.
Downloads
Referências
International Study Group Behçet’s Disease. Criteria for diagnosis of Behçet’s disease. Lancet. 1990;335:1078-1080.
International Team for the Revision of the International Criteria for Behçet’s Disease (ITR-ICBD). The International Criteria for Behçet's Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria. J Eur Acad Dermatol Venereol. 2014;28(3):338-347.
Kural-Seyahi E, Fresko I, Seyahi N, Ozyazgan Y, Mat C, Hamuryudan V, et al. The long-term mortality and morbidity of Behçet syndrome: a 2-decade outcome survey of 387 patients followed at a dedicated center. Medicine (Baltimore). 2003;82:60-76.
Krause I, Uziel Y, Guedj D, Mukamel M, Molad Y, Amit M, et al. Mode of presentation and multisystem involvement in Behçet’s disease: the influence of sex and age of disease onset. J Rheumatol. 1998;25:1566-1569.
Saadoun D, Wechsler B, Desseaux K, Le Thi Huong D, Amoura Z, Resche-Rigon M, et al. Mortality in Behçet’s disease. Arthritis Rheum. 2010;62:2806-2812.
Sfikakis PP. Behcet’s disease: a new target for anti-tumor necrosis factor treatment. Ann Rheum Dis. 2002;61(2):51-53.
Arida A, Fragiadaki K, Giavri E, Sfikakis PP. Anti-TNF agents for Behçet’s disease: analysis of published data on 369 patients. Semin Arthritis Rheum. 2011;41(1):61-70.
Vallet H, Riviere S, Sanna A, Deroux A, Moulis G, Addimanda O, et al. Efficacy of anti-TNF alpha in severe and/or refractory Behçet's disease: Multicenter study of 124 patients. J Autoimmun. 2015;62:67-74.
Mendes D, Correia M, Barbedo M, Vaio T, Mota M, Gonçalves O, et al. Behçet's disease-a contemporary review. J Autoimmun. 2009;32(3-4):178-188.
Kalkan G, Karadag AS, Astarci HM, Akbay G, Ustun H, Eksioglu M. A histopathological approach: when papulopustular lesions should be in the diagnostic criteria of Behçet's disease? J Eur Acad Dermatol Venereol. 2009;23(9):1056-1060.
Cho S, Kim J, Cho SB, Zheng Z, Choi MJ, Kim DY, et al. Immunopathogenic characterization of cutaneous inflammation in Behçet's disease. J Eur Acad Dermatol Venereol. 2014;28(1):51-57.
Levy-Clarke G, Jabs DA, Read RW, Rosenbaum JT, Vitale A, Van Gelder RN. Expert panel recommendations for the use of anti-tumor necrosis factor biologic agentes in patients with ocular inflammatory disorders. Ophthalmology. 2014;121(3):785-796.
Hatemi G, Silman A, Bang D, Bodaghi B, Chamberlain AM, Gul A, et al. EULAR recommendations for the management of Behçet disease. Ann Rheum Dis. 2008;67:1656-1662.
Olivieri I, Leccese P, D'Angelo S, Padula A, Nigro A, Palazzi C, et al. Efficacy of adalimumab in patients with Behçet's disease unsuccessfully treated with infliximab. Clin Exp Rheumatol. 2011;29(4):S54-57.
Aikawa NE, Gonçalves C, Silva CA, Gonçalves C, Bonfá E, de Carvalho JF. Late response to anti-TNF-α therapy in refractory mucocutaneous lesions of Behçet’s disease. Rheumatol Int. 2011;31(8):1097-1099.
Todos os artigos desta revista são de acesso aberto sob a licença internacional Creative Commons Attribution-NonCommercial 4.0 (CC BY-NC 4.0).
